Sorry, you need to enable JavaScript to visit this website.
  1. Home
  3. Science
  4. Clinical Trials
  5. Plain Language Study Results Summaries
  6. Long Term Study Assess Safety

A Long-Term Study to Assess the Safety of Tofacitinib in Participants With Juvenile Idiopathic Arthritis (JIA)

A Long-Term, Open-Label Follow-Up Study of Tofacitinib for Treatment of Juvenile Idiopathic Arthritis (JIA)

Category & Conditions: Immune System Diseases and Conditions
Medicine: XELJANZ®(TOFACITINIB)
ClinicalTrials.gov Identifier (NCT): NCT01500551
Protocol ID: A3921145
DownloadPrint

Open Plain Language Summary Result:

Click here